Dr. Daniel Furst, MD

• Rheumatology

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of California Los Angeles|university Of California San Francisco|university Of California-los Angeles|university Of California-san Francisco

  Fellowship Hospital, 1975

• Johns Hopkins Hospital|the Johns Hopkins Hospital

  Internship Hospital, 1969

• Johns Hopkins School Of Medicine

  Medical School, 1968

• English

• German

• Pneumoproteins KL-6 and CCL-18 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis, 2019-11-01

• Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?, 2008-01-16

• New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN), 2012-05-29

• Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease, 2015-06-30

• Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis, 2017-03-17

• Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease, 2016-12-30

• Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?, 2018-09-07

• An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes-Methodology and Preliminary Results, 2010-09-14

• Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized Trials, 2017-01-06

• 2012 American College of Rheumatology Guidelines for Management of Gout Part I: Systematic Non-pharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia, 2013-05-16

• Predictive Significance of Serum Interferon Inducible Protein Score for Response to Treatment in Systemic Sclerosis Related Interstitial Lung Disease, 2021-04-20

• The Effect of Glucosamine and/or Chondroitin Sulfate on the Progression of Knee Osteoarthritis: A GAIT Report, 2010-02-10

• Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations, 2018-01-02

• Significance of Sex in Achieving Sustained Remission in the Consortium of Rheumatology Researchers of North America (CORRONA) Cohort of Rheumatoid Arthritis Patients, 2012-06-28

• Large-scale characterization of systemic sclerosis serum protein profile: Comparison to peripheral blood cell transcriptome and correlations with skin/lung fibrosis, 2021-02-28

• Study of MRI brain findings and carotid US features in systemic sclerosis patients, relationship with disease parameters, 2019-04-15

• Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control, 2017-02-25

• Course of Modified Rodnan Skin Score in Systemic Sclerosis Clinical Trials: Analysis of 3 Large Multicenter, Randomized Clinical Trials, 2009-05-15

• Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4+T cells in the broncho-alveolar lavage of patients with systemic sclerosis, 2011-09-05

• Equivalent Responses to DMARDs Initiated at Any Time During the First 15 Months After Symptom Onset in Seropositive RA Patients: An Observational Study, 2010-01-28

• Mycophenolate versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II, 2017-05-23

• Clinical Course of Lung Physiology in Patients with Scleroderma and Interstitial Lung Disease: Analysis of the Scleroderma Lung Study Placebo Group, 2011-05-19

• Baseline Characteristics and Follow up in Patients with Normal Hemodynamics vs. Borderline Mean Pulmonary Arterial Pressure in Systemic Sclerosis - Results from the PHAROS Registry, 2012-02-02

• The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases, 2021-08-14

• Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients, 2016-01-20

• Systemic sclerosis is associated with a unique colonic microbial consortium, 2017-07-20

• Cyclophosphamide for Systemic Sclerosis-Related Interstitial Lung Disease: A Comparison of Scleroderma Lung Studies I and II, 2019-02-15

• The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study, 2009-06-22

• Feasibility and Domain Validation of RA Flare Core Domain Set: A Report of the OMERACT 2014 RA Flare Group Plenary, 2015-02-15

• Structural Validity of the Rheumatology Attitudes Index (RAI) in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study, 2017-04-15

• Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study, 2015-09-11

• Myeloablative Autologous Hematopoietic Stem Cell Transplantation Resets the B Cell Repertoire to a more Naive State in Patients with Systemic Sclerosis, 2022-10-14

• Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs, 2017-10-31

• Serum B-cell activating factor and lung ultrasound B-lines in connective tissue disease related interstitial lung disease, 2022-12-15

• Clinical efficacy and safety over two years use of glucosamine, chondroitin sulfate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: a GAIT report, 2010-06-04

• Agreements and Discrepancies between FDA Reports and Journal Papers on Biologic Agents Approved for Rheumatoid Arthritis:A Meta-Research Project, 2016-01-25

• Machine learning predicts stem cell transplant response in severe scleroderma, 2020-09-15

• Differences in Presentation of Younger and Older Systemic Sclerosis Patients in Clinical Trials, 2010-11-03

• Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial, 2016-07-25

• Functional Improvement After RA Patients Start a New Disease Modifying Anti-rheumatic Drug Associated with Frequent Changes in DMARDs: CORRONA Database, 2008-09-01

• Systemic Sclerosis Trial Design Moving Forward, 2018-01-23

• 2012 Update of the 2008 American College of Rheumatology (ACR) Recommendations for the use of Disease-Modifying Anti-Rheumatic Drugs and Biologics in the treatment of Rheumatoid Arthritis (RA), 2014-05-20

• IRF5polymorphism predicts prognosis in patients with systemic sclerosis, 2012-03-22

• Short-term Progression of Interstitial Lung Disease in Systemic Sclerosis Predicts Long-term Survival in Two Independent Clinical Trial Cohots, 2018-11-08

• 2012 American College of Rheumatology Guidelines for Management of Gout Part II: Therapy and Anti-inflammatory Prophylaxis of Acute Gouty Arthritis, 2013-05-16

• Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures, 2019-08-07

• Tocilizumab Prevents Progression of Early Systemic Sclerosis Associated Interstitial Lung Disease, 2021-05-25

• Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report, 2017-08-15

• Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients with Pulmonary Involvement, 2016-05-17

• High-frequency ultrasound of the skin in systemic sclerosis: an exploratory study to examine correlation with disease activity and to define the minimally detectable difference, 2018-08-16

• Updating the OMERACT Filter: Core Areas as a basis for defining core outcome sets, 2014-03-15

• Evaluation of the Satisfaction with Appearance Scale and its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study, 2015-06-01

• TheMUC5BPromoter Variant does not Predict Progression of Interstitial Lung Disease in Systemic Sclerosis, 2020-06-16

• Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to determine efficacy, 2014-07-30

• Current and future outlook on disease modification and defining low disease activity in systemic sclerosis, 2020-05-18